115479-40-8

Basic information

• Product Name: 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine
• Synonyms: 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine;4-Chloro-7-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2,3-O-(1-methylethylidene)--D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-2-amine;9-(5'-O-t-Butyldimethylsilyl-2',3'-O-isopropylidene-b-D-ribofuranosyl)-6-chloro-7-deazaguanine
• CAS NO: 115479-40-8
• Molecular Formula: C₂₀H₃₁ClN₄O₄Si
• Molecular Weight: 455.02
• Product Categories: Carbohydrates & Derivatives;Chiral Reagents;Heterocycles;Carbohydrates & Derivatives, Chiral Reagents, Heterocycles
• Mol File: 115479-40-8.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Refractive Index: 1.603
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine(115479-40-8)
• EPA Substance Registry System: 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine(115479-40-8)

Safety Data

• Hazardous Substances Data: 115479-40-8(Hazardous Substances Data)

Usage

Description

2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is a complex organic compound with a unique chemical structure. It is characterized by the presence of an amino group, a chloro substituent, and a D-ribofuranosyl moiety with isopropylidene and tert-butyldimethylsilyl protecting groups. 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is a valuable intermediate in organic synthesis, particularly in the development of pharmaceuticals and other bioactive molecules.

Uses

Used in Organic Synthesis:
2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of a wide range of derivatives, making it a versatile building block in the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is used as a starting material for the synthesis of novel drug candidates. Its chemical properties and functional groups can be exploited to design and develop new therapeutic agents with improved efficacy and selectivity.
Used in Chemical Research:
2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is also used in chemical research to study the reactivity and properties of various functional groups. Its unique structure provides a platform for investigating new reaction pathways and understanding the fundamental principles of organic chemistry.
Chemical Properties:
2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is a foamy solid, indicating that it has a low melting point and is likely to be sensitive to heat and moisture. This property should be taken into consideration during its synthesis, storage, and handling to ensure the stability and purity of the compound.

InChI:InChI=1/C20H31ClN4O4Si/c1-19(2,3)30(6,7)26-10-12-13-14(29-20(4,5)28-13)17(27-12)25-9-8-11-15(21)23-18(22)24-16(11)25/h8-9,12-14,17H,10H2,1-7H3,(H2,22,23,24)/t12-,13+,14+,17-/m1/s1

Upstream product

• 84955-31-7 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 217309-46-1 5-(tert-butyldimethylsilyloxy)-2,3-isopropylidenedioxy-D-ribofuranose 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 
• 532-20-7 D-Ribose 
• 102690-95-9 5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-β-D-ribofuranosyl chloride 
• 102690-94-8 2,3-O-isopropylidene-5-O-(tert-butyldimethylsilyl)-α-D-ribofuranosyl chloride 

Downstream Products

• 62160-23-0 7-deazaguanosine 
• 444019-16-3 2-[(4-monomethoxytrityl)amino]-7-(2-O-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one 
• 444019-20-9 2-[(p-anisyldiphenylmethyl)amino]-7-(3-deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one 
• 131981-22-1 7-{5'-O-[(1,1-dimethylethyl)dimethylsilyl]-2',3'-O-(1-methylethylidene)-β-D-ribofuranosyl}-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 120401-36-7 2-amino-4-chloro-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 115479-42-0 2-Amino-4-methoxy-7-β-D-ribofuranosylpyrrolo<2,3-d>pyrimidine 
• 62160-23-0 2-amino-7-β-D-ribofuranosylpyrrolo<2,3-d>pyrimidin-4(3H)-one 

Relevant articles and documents

Synthesis and Properties of 2′-OMe-RNAs Modified with Cross-Linkable 7-Deazaguanosine Derivatives

Cross-linkable 7-deaza-6-vinylguanosine (ADVP) and 7-propynyl-7-deaza-6-vinylguanosine (ADpVP) derivatives were synthesized and successfully incorporated into 2′-OMe-RNA oligonucleotides by solid-phase oligonucleotide synthesis. Analysis of their cross-li

S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS

Various embodiments provide STOPS? polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS? modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS? modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE

Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.